Gross Profit Comparison: Amneal Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. Trends

Amneal vs. Taro: A Decade of Diverging Profits

__timestampAmneal Pharmaceuticals, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014449634000580006000
Thursday, January 1, 2015499226000676585000
Friday, January 1, 2016597455000778966000
Sunday, January 1, 2017526178000671251000
Monday, January 1, 2018716403000463508000
Tuesday, January 1, 2019352997000445724000
Wednesday, January 1, 2020628393000399725000
Friday, January 1, 2021768973000296656000
Saturday, January 1, 2022784708000293122000
Sunday, January 1, 2023820565000268323000
Monday, January 1, 2024304979000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Amneal vs. Taro

In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have showcased intriguing trends in their gross profits over the past decade. From 2014 to 2023, Amneal's gross profit surged by approximately 82%, peaking in 2023. In contrast, Taro experienced a decline of around 54% during the same period, with its lowest point in 2023. This divergence highlights the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to vastly different financial outcomes. Notably, Amneal's consistent growth reflects its robust market strategies, while Taro's challenges underscore the volatility and risks inherent in the sector. As we look to the future, the absence of data for Amneal in 2024 leaves room for speculation, while Taro shows signs of recovery. This comparison offers valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025